MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/75/0.2/20.06.25 | Market Closed - Bid/Ask 11:44:15 2024-06-26 EDT | After market 14:48:51 | |||
| 13.59 EUR | -3.62% |
|
13.76 | +1.25% |
| Current month | +19.49% | ||
| 1 month | +15.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 13.59 | -3.62% |
| 24-06-25 | 14.1 | +6.33% |
| 24-06-24 | 13.26 | -0.75% |
| 24-06-21 | 13.36 | -0.60% |
| 24-06-20 | 13.44 | +1.66% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 11:44 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MB70VS |
| ISIN | DE000MB70VS9 |
| Date issued | 2023-06-06 |
| Strike | 75 $ |
| Maturity | 2025-06-20 (359 Days) |
| Parity | 5 : 1 |
| Emission price | 3.91 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.1 € |
|---|---|
| Lowest since issue | 2.98 € |
| Spread | 0.02 € |
| Spread % | 0.15% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,028
DKK
Average target price
938.1
DKK
Spread / Average Target
-8.74%
- Stock Market
- Warrants
- Warrant
